Minghui Pharmaceutical said it has signed a deal to sell its Japanese rights for a Phase 3 thyroid eye disease drug to a specialty pharma with long ties to thyroid hormone products. The transaction includes $110 million in upfront payments, according to the report. The licensing agreement highlights how late-stage assets in ophthalmic autoimmune disease are attracting cross-border partnering, with Japan rights representing a route to commercial scale while the China-based developer retains other regions. For industry observers, it also signals continued capital flow into programs progressing toward regulatory filing. As the asset enters late-stage commercialization planning, the main watch item will be how partner strategy aligns with the expected Japanese regulatory and market dynamics for thyroid eye disease.